Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 746 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Glycemic Control Clear all
Completed Not applicable Interventional

A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM

NCT00308451
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)
Drug
Lead sponsor
Nutrition 21, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2006 · Synced Oct 20, 2026, 9:22 AM EDT
Active, not recruiting Not applicable Interventional Results available

Assessing Gut Microbiota Mediated Health Outcomes of Whole Wheat and Its Major Bioactive Components

NCT05318183
View directory record Official record
Conditions
PreDiabetes, Dysbiosis, Endotoxemia, Inflammation
Interventions
Whole Wheat Bread, White Bread (control)
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 20, 2026, 9:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

Breakthrough - T1DM and Chronic Kidney Disease

NCT07592000
View directory record Official record
Conditions
Diabete Type 1, Chronic Kidney Disease
Interventions
Tegoprubart, Islet Cell Transplant
Drug · Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Miami, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 20, 2026, 9:22 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Dihydroberberine Effects on Body Composition and Metabolic Health in Healthy Adults

NCT07322679
View directory record Official record
Conditions
Health Adult Subjects
Interventions
Placebo （Microcrystalline Cellulose）, Dihydroberberine（DHB）
Dietary Supplement
Lead sponsor
Nanjing Nutrabuilding Bio-tech Co., Ltd.
Other
Eligibility
35 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Evaluate the Effect of Naturlose (Tagatose)

NCT00961662
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
D-Tagatose
Drug
Lead sponsor
Robert Lodder
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Garden Grove, California • Miami, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 20, 2026, 9:22 AM EDT
Completed No phase listed Observational

TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study

NCT01364350
View directory record Official record
Conditions
Diabetes Mellitus Type 2 in Obese
Interventions
standard of care in general clinical practice
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 24 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
16
States / cities
Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Optimizing Self-Management Adherence and Glycemic Control in Older Teens With Type 1 Diabetes: The Teenwork Study

NCT01892280
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Teenwork intervention, Text message reminders
Behavioral
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
13 Years to 17 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 20, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets

NCT07502495
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
icovamenib 100mg, Placebo
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • Canoga Park, California • Fountain Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)

NCT03651622
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Overweight and Obesity
Interventions
Hypocaloric, low carbohydrate diet, Hypocaloric, moderate low fat diet, Mediterranean diet, no caloric restriction
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
19 Years to 30 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Palo Alto, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

Improving Glycemic Control in DM2 Patients in the Ambulatory Setting

NCT04800471
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Smart insulin pens and CGM, Point of Care Glucose Group
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Results available

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

NCT01524705
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin Glargine, Metformin, Prandial insulin, Exenatide
Drug
Lead sponsor
University of Washington
Other
Eligibility
40 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 20, 2026, 9:22 AM EDT
Terminated Phase 3 Interventional

Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes

NCT00427154
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
rosiglitazone, inhaled human insulin, metformin, glimepiride
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
103
States / cities
Hueytown, Alabama • Ozark, Alabama • Tuscaloosa, Alabama + 95 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 20, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

Preventing Injured Knees From osteoArthritis: Severity Outcomes

NCT06096259
View directory record Official record
Conditions
Osteoarthritis, Knee, Post-traumatic Osteoarthritis, ACL Tear
Interventions
Metformin, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
9
States / cities
Atlanta, Georgia • Iowa City, Iowa • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 9:22 AM EDT
Not listed Not applicable Interventional

Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D

NCT04614623
View directory record Official record
Conditions
Type1diabetes
Interventions
AHCL pump, Video conferencing Application
Device · Other
Lead sponsor
Children's Hospital New Orleans, LA
Other
Eligibility
10 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Altering Physical Activity on Cardiometabolic Health

NCT01879059
View directory record Official record
Conditions
Insulin Resistance
Interventions
Exercise
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
19 Years to 35 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

The Role of Apathy in Glycemic Control

NCT00844090
View directory record Official record
Conditions
Apathy, Diabetes
Interventions
methylphenidate or placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 20, 2026, 9:22 AM EDT
Recruiting Not applicable Interventional

Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes

NCT06836479
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
Interventions
NOURISH Diet, Self-Selected Diet (Control)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 3 Interventional

Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment

NCT00046462
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Lantus (insulin glargine [rDNA origin] injection), Metformin, Glyburide, Thiazolidinedione
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Not applicable Interventional

The Diabetes Telemonitoring (DiaTel) Study

NCT00245882
View directory record Official record
Conditions
Diabetes
Interventions
Care Coordination, Home Telemedicine
Behavioral
Lead sponsor
United States Department of Defense
Federal
Eligibility
18 Years to 79 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Intensive Glycemic Control and Skeletal Health Study

NCT00324350
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Coronary Disease
Interventions
hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 79 Years
Enrollment
7,287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
4
States / cities
Minneapolis, Minnesota • Winston-Salem, North Carolina • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 20, 2026, 9:22 AM EDT
Not listed No phase listed Observational

Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin

NCT04034524
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GLP-1 receptor agonist, Insulin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy

NCT01240759
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
S-707106 Dose A, S-707106 Dose B, S-707106 Dose C, Placebo A tablet, Metformin
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 20, 2026, 9:22 AM EDT
Enrolling by invitation No phase listed Observational

Liver Transplant CGM

NCT07216508
View directory record Official record
Conditions
Liver Transplant, Post Transplant Diabetes, Type 2 Diabetes
Interventions
Libre 3+
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 20, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control

NCT00945659
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Continuous Glucose Sensor, Standard Care, CGS + Behavior Therapy
Device · Other · Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
11 Years to 16 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 20, 2026, 9:22 AM EDT